Cambrex Announces Sale of Drug Product Business Unit
Cambrex completed the sale of its Drug Product Business Unit to Wilmington, Delaware based Noramco. Cambrex’s Drug Product business provides product development, clinical and commercial manufacturing, and packaging from facilities in Mirabel, Québec, Canada and Whippany, New Jersey, USA.
Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API Development
Cambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial Agreement